Kezar Life Sciences Files 8-K with Key Updates

TL;DR

Kezar Life Sciences dropped an 8-K detailing material agreements, financial updates, and security holder rights changes.

AI Summary

Kezar Life Sciences, Inc. filed an 8-K on October 16, 2025, reporting on several key events. These include entering into a material definitive agreement, updates on results of operations and financial condition, material modifications to the rights of security holders, and other events. The filing also includes financial statements and exhibits.

Why It Matters

This 8-K filing provides crucial updates on Kezar Life Sciences' operational and financial status, as well as changes affecting its security holders, which are important for investors to monitor.

Risk Assessment

Risk Level: medium — The filing indicates material definitive agreements and modifications to security holder rights, which can introduce significant business and financial risks.

Key Players & Entities

• Kezar Life Sciences, Inc. (company) — Registrant
• October 16, 2025 (date) — Date of earliest event reported
• 4000 SHORELINE COURT, SUITE 300 (address) — Business and Mail Address
• SOUTH SAN FRANCISCO, CA 94080 (address) — Business and Mail Address
• 650-822-5600 (phone_number) — Business Phone

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value KZR The Nasdaq Stock Market L
• $90.2 million — s and marketable securities position of $90.2 million as of September 30, 2025. A copy of the

Filing Documents

• kzr-20251016.htm (8-K) — 33KB
• kzr-rightsagreementamendme.htm (EX-4.1) — 26KB
• kzr-10x16x25pr.htm (EX-99.1) — 20KB
• 0001628280-25-045215.txt ( ) — 252KB
• kzr-20251016.xsd (EX-101.SCH) — 3KB
• kzr-20251016_def.xml (EX-101.DEF) — 16KB
• kzr-20251016_lab.xml (EX-101.LAB) — 29KB
• kzr-20251016_pre.xml (EX-101.PRE) — 17KB
• kzr-20251016_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. The information set forth under "Item 3.03 Material Modification to Rights of Security Holders" of this Current Report on Form 8-K is incorporated into this Item 1.01 by reference.

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On October 16, 2025, Kezar Life Sciences, Inc. (the "Company") issued a press release announcing a regulatory update on its zetomipzomib program in autoimmune hepatitis, its plans to explore strategic alternatives and the Amendment to the Rights Agreement (discussed below). The press release included the Company's preliminary cash, cash equivalents and marketable securities position of $90.2 million as of September 30, 2025. A copy of the Company's press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information provided in this Item 2.02 of this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

03 Material Modification to Rights of Security Holder

Item 3.03 Material Modification to Rights of Security Holder. On October 16, 2025, the Company entered into Amendment No. 2 (the "Amendment") to the Rights Agreement, dated as of October 17, 2024, as amended on December 3, 2024, by and between the Company and Computershare Trust Company, N.A., as rights agent (as amended, the "Rights Agreement"). Capitalized terms used but not otherwise defined in this Item 3.03 shall have the meanings ascribed to such terms in the Rights Agreement. The Amendment extends the Final Expiration Date of the Ri ghts Agreement to the day following the certification of the voting results of the Company's 2026 annual meeting of stockholders or, if at such meeting the Company's stockholders approve or ratify the Rights Agreement, to the day following the certification of the voting results of the Company's 2027 annual meeting of the stockholders, unless the Rights are earlier redeemed or exchanged by the Company. The Rights Agreement otherwise remains unmodified and i n full force and effect in accordance with its terms. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Amendment, a copy of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and incorporated by reference into this Item 3.03.

01 Other Events

Item 8.01 Other Events. The information set forth under "Item 2.02 Results of Operations and Financial Condition " of this Current Report on Form 8-K, except for the Company's preliminary cash position as of September 30, 2025, is incorporated into this Item 8.01 by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Amendment No. 2, dated as of October 16 , 2025 , to Rights Agreement, dated as of October 17, 2024, as amended on December 3, 2024, by and between Kezar Life Sciences, Inc. and Computershare Trust Company, N.A., as rights agent 99.1 Press Release, dated October 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEZAR LIFE SCIENCES, INC. Date: October 16, 2025 By: /s/ Marc L. Belsky Marc L. Belsky Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR